Together with Mareike Göritz and Matthias Stein-Gerlach, Dieter Link is responsible for technology transfer in the life-sciences section. Prior to working for Max Planck Innovation he held various positions with Xantos Biomedicine AG in Munich and, among others, has been responsible for the implementation of novel cell-based assay technologies and for establishing the company's metabolic disease program.
He studied microbiology, biochemistry and human genetics at the Johann Wolfgang Goethe University in Frankfurt, where he wrote his doctoral thesis at the University's Institute of Human Genetics. During his academic career, he initially focused on the control of gene expression in microorganisms, and later on cellular differentiation mechanisms in mammals.
Dieter Link joined Max Planck Innovation in February 2006.
Together with Dieter Link and Mareike Göritz, Matthias Stein-Gerlach is responsible for technology transfer in the life-sciences section. He is co-founder of the biotech companies Axxima Pharmaceuticals AG, Munich, and U3 Pharmaceuticals AG, Martinsried. After heading his own research group at Axxima, starting 1998, he became Director Business Development in 2001 and was appointed VP Business Development in 2002, heading the business development department until 2004.
He studied molecular biology in Mainz and earned his PhD in 1998 in the lab of Dr Axel Ullrich of Max Planck Institute for Biochemistry in Martinsried with a thesis focusing on signal transduction. In addition, Matthias Stein-Gerlach has completed a 3 year education in finance and administration at the Adam Opel AG.
Matthias Stein-Gerlach joined Max Planck Innovation in April 2004.
Together with Dieter Link and Matthias Stein-Gerlach, Mareike Göritz is responsible for technology transfer in the life-sciences section. She studied chemistry at the universities of Erlangen-Nuremberg, Valencia (Spain) and California, Berkeley (USA). She obtained her PhD in bioinorganic chemistry from the University of Heidelberg where she worked on functionalized nucleic acids for sequence-specific detection of DNA. As a postdoctoral researcher at the California Institute of Technology in Pasadena she studied the regulation of gene transcription by small DNA-binding molecules in living cells.
Mareike Göritz joined Max Planck Innovation in July 2009.
Together with Wolfgang Tröger, Bernd Ctortecka is responsible for technology transfer in the chemistry, physics and technology section, as well as for the know-how transfer of software from the Max Planck Society.
Bernd Ctortecka began his career in banking. He then studied physics at the Albert Ludwigs University in Freiburg i.Br. and at the University of St. Andrews, Scotland, UK, and completed his Master of Philosophy (M.Phil) with a thesis on NMR studies of superconductors. He wrote his doctoral thesis on comparative studies of metal sites in copper proteins with synthetic macromolecules at the Faculty of Physics at Leipzig University, including regular stays at the isotope separator ISOLDE at CERN, Geneva, the Paul Scherrer Institute (PSI) in Villigen, Switzerland, and the Chalmers University Gothenburg. One aspect of the PSI collaboration was the development of a radio pharmacon based on the isotope 111Ag. Subsequently, he worked in a Munich-based patent law firm and became internal key account manager at Infineon Technologies AG.
Bernd Ctortecka joined Max Planck Innovation in January 2002.
Together with Bernd Ctortecka, Wolfgang Tröger is responsible for technology transfer in the chemistry, physics and technology section of the Max Planck Society. Following his physics studies at the Technical University of Munich (TUM), he earned his PhD at the Max Planck Institute for Biochemistry in Martinsried and the Physics Department of TUM. Following periods of research in Paris and Copenhagen, he habilitated at Leipzig University. His research interest focused on the application of nuclear techniques and other spectroscopic methods in the life, environmental and material sciences. The interdisciplinary approach of his research at the borderline between physics, chemistry and biology endowed him with a broad experience in these fields, which was an invaluable input for his industry cooperation.
Wolfgang Tröger joined Max Planck Innovation in September 2004.
Together with Wolfgang Tröger and Bernd Ctortecka, Lars Cuypers is responsible for technology transfer in the chemistry, physics and technology section. He studied chemistry at the Carl von Ossietzky University Oldenburg and devoted his diploma thesis to the field inorganic molecule chemistry. Than he changed to the Philipps University Marburg for his conferral of a doctorate focusing on hydrogallation and the synthesis of gallium clusters. He gained first business experience at the graduate program of the speciality chemistry company Clariant, working on different research and development projects regarding fields like metal working fluids, crop protection, personal care and detergents. The following function as a laboratory manager in the field detergent raw materials enabled him to contribute his services to major projects with direct customer contact.
Lars Cuypers joined Max Planck Innovation in May 2007.
Katharina Miller has been employed for patent and license management in the life science division since January 2016. She graduated her Bachelor´s and Master´s Degree in biology at the Technische Universität München (TUM). During her PhD studies at the Klinikum rechts der Isar of the TUM in the field of pancreas tumor research she analyzed the role of the type I interferon receptor during inflammation and regeneration in the adult murine pancreas. Katharina Miller will carry out patent and market research in the context of invention disclosure evaluation at Max Planck Innovation and will support Max-Planck-Innovation until December 2017.
Doris Maugg, who has a doctorate in biology, started working for patent- and license management at Max Planck Innovation on 1. October 2016. She graduated at the Technische Universität München (TUM) and did her PhD studies at the Ludwig-Maximilians-Universität München. Here she investigated how ionizing radiation leads to epigenetic alterations of specific chromatin regions. In recent years Dr Maugg focused on the development of new therapies against osteosarcoma within a clinical cooperation group of TUM and Helmholtz Zentrum München. Dr Maugg will carry out patent and market research in the context of invention disclosure evaluation at Max-Planck-Innovation and will support Max-Planck-Innovation until September 2018.